X0407 4 2023-03-22 0001737287 Allogene Therapeutics, Inc. ALLO 0001611024 Chang David D 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 true true President and CEO false Common Stock 2023-03-22 4 A false 1924464 0 A 4193911 D Common Stock 1201108 I See footnote Common Stock 856044 I See footnote Common Stock 856044 I See footnote Stock Option (Right to Buy) 5.04 2023-03-22 4 A false 1492200 0 A 2033-03-22 Common Stock 1492200 1492200 D Includes 1,480,357 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period. Securities held in the name of the Chang 2006 Family Trust Securities held in the name of the JEC 2019 Trust dated October 1, 2019. Securities held in the name of the RTC 2019 Trust dated October 1, 2019. 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. /s/Veer Bhavnagri, Attorney-in-Fact 2023-03-24